Skip to content
Open access

Personalized neoantigen vaccine platform and longitudinal tracking of vaccine-related clonotypes enable the identification of tumor-specific TCRs

Sep 2026 · Cancer Immunology and Immunotherapy · 0 citations

TL;DR

This proof-of-concept study demonstrates that personalized neoantigen vaccination can induce durable and diverse tumor-specific T-cell responses in ovarian cancer and establishes a framework for using vaccination as an in vivo platform to identify clinically relevant tumor-specific TCRs for future cellular therapies.

Abstract

Effective immunotherapeutic strategies for high-grade serous ovarian cancer (HGSOC) remain limited despite evidence of tumor immunogenicity. Here, we report the longitudinal immune characterization of a patient with homologous recombination-deficient HGSOC treated with a personalized neoantigen-based dendritic cell (DC) vaccine during maintenance therapy with the PARP inhibitor olaparib. Following neoadjuvant chemotherapy and interval debulking surgery, the patient in complete response received an autologous monocyte-derived DC vaccine loaded with seven synthetic patient-specific neoantigen peptides (PEP-DC). The vaccine was well tolerated, with no serious vaccine-related adverse events. Comprehensive immune monitoring using flow cytometry, IFN- γ ELISpot assays, and bulk and single-cell T-cell receptor (TCR) sequencing revealed durable induction of neoantigen-specific immune responses, including polyfunctional T-cell responses and expansion of both de novo and pre-existing vaccine-related T-cell clonotypes. By integrating longitudinal TCR repertoire profiling with functional validation assays, we identified one vaccine-specific CD4 TCR and two CD8 TCRs recognizing tumor neoantigens. This proof-of-concept study demonstrates that personalized neoantigen vaccination can induce durable and diverse tumor-specific T-cell responses in ovarian cancer and establishes a framework for using vaccination as an in vivo platform to identify clinically relevant tumor-specific TCRs for future cellular therapies.

Read PDF

Similar papers

Review Open access Sep 2026

Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade

By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combinati...

T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al. · 0 citations
Open access Oct 2026

Discovery of frameshift-associated TCRs following personalized neoantigen vaccination in a patient with osteosarcoma

Personalized antigen-directed immunotherapies, including personalized cancer vaccines, are emerging as promising therapeutic modalities for a range of cancer types. Immune monitoring can be used to evaluate the efficacy of a vaccine in stimulating the immune response pre- and post-vaccination; however, such approaches...

Sarah N. Bennett, Jessica R. Alley, Mitra Shabrang et al. · 0 citations
Clinical trial Open access Sep 2026

Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized...

Felicia Zhang Perkins, Xiu-Li Zhang, Y. Yu et al. · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations
Review Open access Aug 2026

From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines

This hypothesis framework proposes seven sequential gates for antigen-defined, HLA-restricted T-cell vaccines: tumor specificity, natural peptide–HLA presentation, population coverage, persistence under immune selection, selective T-cell recognition, manufacturability, and randomized clinical benefit.

Sarfaraz K. Niazi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.